SynthesisJournal of ovarian research2026
Impact of pre-operative frailty on short-term outcomes of ovarian cancer: a systematic review and meta-analysis.
Synthesis in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFrailty has been linked to adverse outcomes after numerous surgical procedures; however, its utility for ovarian cancer patients undergoing surgery remains undefined. We systematically reviewed literature to examine the risk of short-term adverse events in surgically treated ovarian cancer patients based on the presence of frailty.
methodsWeb of Science, Embase, PubMed and Scopus databases were searched for all observational studies published from the inception of the databases to 14 August 2025. Data on all complications, major complications, minor complications, mortality and readmission were pooled in a random effects model.
resultsEleven studies were included. Meta-analysis showed that the presence of frailty was associated with a statistically significant increase in the risk of all complications (OR: 1.61 95% CI: 1.35, 1.92 I2 = 44%) and major complications (OR: 1.80 95% CI: 1.31, 2.47 I2 = 54%) in patients with ovarian cancer. Meta-analysis showed that the presence of frailty did not significantly increase the risk of minor complications (OR: 1.39 95% CI: 0.93, 2.07 I2 = 0%) or mortality (OR: 1.12 95% CI: 0.59, 2.12 I2 = 0%) in patients with ovarian cancer. However, the risk of readmission was increased with the presence of frailty (OR: 1.43 95% CI: 1.11, 1.84 I2 = 0%). Subgroup analysis conducted based on location, frailty assessment tools, including only stage III/IV disease, and reporting of adjusted data demonstrated mixed results. Meta-regression analysis showed that a higher surgical complexity score was associated with increased risk of major complications.
conclusionsPretreatment frailty seems to be associated with increased risk of complications in ovarian cancer patients undergoing surgery. However, due to minimal evidence, no clear association could be found between frailty and risk of short-term mortality and minor complications. Further prospective, adequately powered studies using similar frailty assessment tools and cut-offs are needed from different regions of the world to provide better evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.